Overview

Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD

Status:
Completed
Trial end date:
2020-08-28
Target enrollment:
Participant gender:
Summary
This is an open label randomized 24 week crossover trial assessing the treatment burden of a weekly growth hormone injection regimen (somatrogon) compared to a daily growth hormone injection regimen (Genotropin). Approximately 90 children with growth hormone deficiency who have been stable on treatment with daily Genotropin will be enrolled.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Hormones